Observational studyBMC infectious diseases2026
Admission lipid profile and outcomes in sepsis requiring early invasive source control.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLipid metabolism is profoundly altered in sepsis, but its prognostic utility is underused in clinical practice. We evaluated lipid profiles performed within 24-48 h of ICU admission in patients with sepsis or septic shock who had already undergone surgical or interventional source control and explored associations with organ support and hospital mortality.
methodsWe conducted a single-center retrospective observational cohort study at the intensive care unit of Hospital Universitari Sant Joan de Reus (2016-2023). We included adults meeting Sepsis-3 criteria who underwent surgical or interventional source control within 48 h of hospital arrival. Only patients with available lipid profiles were included, which may introduce selection bias. Hospital mortality was defined as the primary clinical outcome. Secondary outcomes included organ support requirements, ICU and hospital length of stay, correlations with SOFA severity scores, and inflammatory biomarkers. Multivariable logistic regression models were constructed as an exploratory analysis to investigate the independent associations between lipid parameters and hospital mortality.
resultsOf 266 screened patients, 150 met the inclusion criteria, comprising 61.3% males, with a median age of 72.1 years (IQR, 61.7-79.8), and an overall hospital mortality rate of 18.7% (n = 28). Non-survivors exhibited significantly lower concentrations of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and total cholesterol levels, and higher triglyceride levels than survivors. In ROC analyses, HDL-C showed the highest accuracy (AUC 0.966, 95% CI 0.904-1.000), with an optimal cutoff of 15 mg/dL, sensitivity of 96.4%, and specificity of 98.3%. This was followed by total cholesterol (AUC 0.963, 95% CI 0.901-1.000) and LDL-C (AUC 0.920, 95% CI 0.851-0.989). In contrast, triglycerides demonstrated a more modest predictive performance (AUC 0.849, 95% CI 0.772-0.926). In multivariable analysis, lower HDL-C levels (OR 0.802, 95% CI 0.727-0.885; p < 0.001) and lower albumin levels (OR 0.241, 95% CI 0.066-0.879; p = 0.031) remained independently associated with hospital mortality in the final parsimonious model derived using backward stepwise selection from an initial candidate model including chronic kidney disease, CRRT requirement, vasopressor use, LDL-C, VLDL-C, and triglycerides.
conclusionsEarly hypolipidemia was independently associated with hospital mortality in septic patients undergoing timely source control. Post-source control lipid alterations may reflect residual immunometabolic vulnerability and warrant further evaluation as exploratory prognostic biomarkers. Nevertheless, given the retrospective observational design and limited sample size, these results should be interpreted as hypothesis-generating and require prospective external validation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.